BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January

Day

• 1
• 2
• 5
• 6
• 7
• 8

• 

  Drug pricing

  Despite MFN Deals, Drug Pricing Will Dog Pharma Into 2026

  Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller biotechs continue to hang in limbo.

  January 6, 2026

   · 

  5 min read

   · 

  Annalee Armstrong
• 

  Manufacturing

  2026: Putting the Reindustrialization Mandate Into Practice

  Industry leaders are focused on the resilience of key starting material supply and the knock-on effects of automation in the new year.

  January 6, 2026

   · 

  4 min read

   · 

  Nick Paul Taylor
• 

  Opinion

  Automated Manufacturing Will Meet CAR T Demand

  Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, global consistency and broader patient access to CAR T therapies.

  January 6, 2026

   · 

  3 min read

   · 

  Ossama Eissa
• 

  Cancer

  Gilead Keeps Dealing With $300M OncoNano Drug Delivery Cancer Pact

  OncoNano’s platform, called ON-BOARD, packages drugs in pH-sensitive micelles that ensure their specific delivery near tumors, while also preventing systemic exposure.

  January 6, 2026

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Obesity

  Roche Clears Obesity Pill Legal Concerns With Structure Patent Agreement

  The agreement, which BMO Capital Markets called a “mild positive” for Structure, appears to address Roche’s concerns about the composition of investigational weight loss drug CT-996.

  January 6, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Immunology and inflammation

  Zenas Plummets After Late-Stage Data Fall Short of Amgen in Inflammatory Disease

  While Zenas’ obexelimab hit the primary endpoint in the Phase III INDIGO study, it came far below the efficacy threshold set by Amgen’s B cell depleter Uplizna, approved by the FDA for IgG4-related disease last April.

  January 6, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Vaccines

  Vaccine Investors Keep Their Heads Down as Trump Cuts Shot Schedule

  The US dramatically altered its recommendations for a series of vaccines, which drive billion-dollar earnings for giants like Merck and Pfizer.

  January 6, 2026

   · 

  3 min read

   · 

  Dan Samorodnitsky
• 

  Weight Loss

  Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study

  Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and enhance weight loss as compared to tirzepatide alone, particularly in patients with type 2 diabetes.

  January 6, 2026

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  FDA

  FDA Went Against Adcomm Votes More, Held Fewer Meetings in 2025

  In a year that saw advisory committees placed under a particularly bright microscope at the FDA, the agency held fewer meetings than usual and agreed with its advisors only 57% of the time, Jefferies reported.

  January 6, 2026

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Obesity

  Lilly Doubles Down With Nimbus, Paying $55M for Preclinical Obesity Drug

  Eli Lilly kicked off a pivotal 2026 campaign with a multi-year collaboration with current partner Nimbus Therapeutics worth a potential $1.3 billion for a preclinical obesity therapeutic. The deal follows a 2022 partnership struck by the companies to target the AMPK protein in cardiometabolic diseases.

  January 6, 2026

   · 

  2 min read

   · 

  Heather McKenzie